Minghui Pharmaceutical gets FDA green light for Phase III trials of its therapy in thyroid eye disease
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
Ryght AI tackles these hurdles with its AI Site Twin platform
This launch is part of the company's strategy to expand its nutraceutical portfolio
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Clinical trial enrollment has long been a bottleneck in drug development
Subscribe To Our Newsletter & Stay Updated